

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

1-34. Cancelled.

35. (Previously presented) A complex comprising first and second peptides, the first peptide comprising the V3 loop of gp120, and wherein the V3 loop is ~~coordinated with bound to~~ a binding region on the second peptide, the binding region on the second peptide comprising at least residues 21-40 and 46-58 of the Tat protein set forth in SEQ ID NO 1, or a fragment, mutant or variant thereof capable of binding a region on gp120 comprising residues 301-419 of SEQ ID NO. 2.

36. (Currently amended) A complex comprising first and second peptides, the first peptide comprising the V3 loop of gp120, and wherein the V3 loop is ~~coordinated with bound to~~ a binding region on the second peptide, the binding region on the second peptide being derived from Tat and being recognisable by ~~the a~~ monoclonal antibody directed against the CCR5 second extracellular loop ~~described by Lee, B., et al., J. Biol. Chem., 1999, Vol. 274, 9647-9656.~~

37. (Currently amended) The complex of claim ~~34~~ 35, wherein the binding region comprises at least residues 21-58 of SEQ ID NO 1, or a fragment, mutant or variant thereof capable of binding residues 301-419 of SEQ ID NO. 2.

38. (Currently amended) The complex of claim ~~34~~ 35, prepared with ~~non-oxidised~~ native Tat.

39. (Currently amended) The complex of claim ~~34~~ 35, wherein the peptide comprising the V3 loop comprises some or all of ~~Env~~ gp120 in addition to the V3 loop.

40. (Currently amended) The complex of claim ~~34~~ 35, wherein the peptide comprising the V3 loop comprises the complete sequence of SEQ ID NO 2, or a fragment, variant or mutant thereof capable of binding a peptide consisting of residues 21-58 of SEQ ID NO 1.

41. (Currently amended) The complex of claim ~~34~~ 35, wherein the peptide comprising the V3 loop consists of the V3 loop region of gp120.

42. (Currently amended) The complex of claim ~~34~~ 35, wherein the peptide comprising the V3 loop comprises at least residues 301-419 of SEQ ID NO. 2, or a fragment, variant or mutant thereof capable of binding a peptide consisting of residues 21-58 of SEQ ID NO 1.

43. (Currently amended) The complex of claim ~~34~~ 35, having all or part of gp160 as a component thereof, the gp160 comprising at least the V3 loop of gp120 and lacking at least the majority of the V2 loop of gp120.

44. (Currently amended) The complex of claim ~~34~~ 35, having Δ V2Env as a component thereof.

45. (Currently amended) The complex of claim ~~34~~ 35, wherein the peptide comprising the V3 loop comprises at least residues 301 to 419 as shown in SEQ ID NO. 2.

46. (Currently amended) The complex of claim ~~34~~ 35, further comprising a molecule or substance capable of interacting with Env to expose a functional V3 loop.

47. (Previously presented) The complex of claim 46, wherein said molecule or substance is CD4 or a fragment, mutant or variant thereof.

48. (Currently amended) The complex of claim ~~34~~ 35, further comprising a heparan sulphate, ~~optionally further comprising at least one other molecule capable of binding said heparan sulphate.~~

49. (Currently amended) The complex of claim ~~34~~ 35, further comprising a substance selected from the group consisting of integrins, basic fibroblast growth factor, CD26, VEGF receptors, and chemokine receptors.

50. (Currently amended) The complex of claim ~~34~~ 35, wherein the binding region is contained within a fragment of Tat generatable by proteasomes of human cells on exposure to Tat, wherein the Tat fragment from the group consisting of fragments containing the cysteine, basic and RGD regions of Tat; fragments containing the cysteine and basic regions of Tat; fragments containing the basic and

RGD region of Tat; and, fragments containing the basic region of Tat, alone.

51. Cancelled

52. (Currently amended) The complex of claim ~~34~~ 35, wherein said peptides are cross-linked.

53. (Currently amended) Use of the complex of claim ~~34 to generate~~ 35 in an immunogenic composition for generating antibodies thereagainst.

54. (Currently amended) The use of the immunogenic composition of claim 53 in a process to obtain a monoclonal cell line.

55. (Currently amended) The use of claim 53, wherein the antibodies are selected such as not to recognise any of the epitopes of the group of native Tat, gp160, CD4 or gp120, CCR5, and the V3 loop region of gp120 also recognized by antibodies generated by one of the group when used as immunogen in isolation but only as the complex of claim ~~34~~ 35.

56. (Previously presented) An antibody obtained by a process as defined in claim 52.

57-62. Cancelled.

63. (Currently amended) ~~The complex of claim 34-35, provided as a combination of the peptides in a~~ A vehicle suitable for injection comprising the complex of claim 35.

64. (Currently amended) A kit comprising at least two separate preparations of the components of the complex of claim ~~34~~ 35.

65. (Currently amended) Use of the complex of claim ~~34~~ 35 in therapy.

66. (Currently amended) A method for the treatment or prophylaxis of a viral infection, whereby the infecting virus expresses a molecule capable of forming a ternary complex between said molecule, CD4 and CCR5, comprising administering the complex of claim ~~34~~ 35 to patient in need thereof .

67. (Currently amended) Use of the complex of claim ~~34~~ 35 to establish whether a sample from a patient contains antibodies against said complex.